SOLBRI
Valeant International Bermuda
Application Filed: 2011-05-10
Trademark Application Details
ABANDONED - NO STATEMENT OF USE FILED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 85317171 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Christopher L. Graff |
| Attorney Docket Number | VPBV002 |
| Law Office Assigned | L50 |
| Employee Name | TENG, SIMON |
Timeline
| 2011-05-10 | Application Filed |
| 2014-05-06 | Published for Opposition |
| 2015-02-12 | Location: INTENT TO USE SECTION |
| 2016-08-01 | Abandon |
| 2016-08-01 | Status: Dead/Abandoned |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Valeant International Bermuda |
| Address | 2 Church Street Clarendon House Hamilton BM HM11 |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | BM |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations and substances for use in chemotherapy; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditions |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2011-05-13 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2011-05-16 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2011-08-24 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2011-08-24 | 4 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2011-08-24 | 5 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2011-08-24 | 6 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2012-02-23 | 7 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2012-02-23 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2012-02-23 | 9 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2012-02-24 | 10 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2012-02-24 | 11 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2012-02-24 | 12 GNS3 O:Outgoing Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2012-08-01 | 13 ASCK I:Incoming Correspondence |
| ASSIGNED TO LIE | 2012-08-27 | 14 ALIE A:Allowance for Publication |
| LIE CHECKED SUSP - TO ATTY FOR ACTION | 2012-08-27 | 15 RCCK S: |
| SUSPENSION INQUIRY WRITTEN | 2012-08-28 | 16 CNSI R:Renewal |
| INQUIRY TO SUSPENSION E-MAILED | 2012-08-28 | 17 GNSI S: |
| NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | 2012-08-28 | 18 GNS2 O:Outgoing Correspondence |
| TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | 2013-02-27 | 19 ERSI I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2013-03-07 | 20 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2013-03-07 | 21 TEME I:Incoming Correspondence |
| NON-FINAL ACTION WRITTEN | 2013-03-18 | 22 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2013-03-18 | 23 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2013-03-18 | 24 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2013-09-11 | 25 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2013-09-12 | 26 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2013-09-12 | 27 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2013-09-30 | 28 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2013-09-30 | 29 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2013-09-30 | 30 GNFN O:Outgoing Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2014-01-22 | 31 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2014-01-22 | 32 ARAA I:Incoming Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2014-03-12 | 33 ERFR I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2014-03-12 | 34 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2014-03-13 | 35 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2014-04-01 | 36 CNSA P: |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2014-04-01 | 37 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2014-04-16 | 38 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2014-05-06 | 39 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2014-05-06 | 40 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2014-07-01 | 41 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2014-12-18 | 42 EEXT I:Incoming Correspondence |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2015-01-21 | 43 ASCK I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2015-02-12 | 44 AITU A:Allowance for Publication |
| EXTENSION 1 FILED | 2014-12-18 | 45 EXT1 S: |
| EXTENSION 1 GRANTED | 2015-02-18 | 46 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2015-02-19 | 47 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2015-06-29 | 48 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2015-06-29 | 49 EXT2 S: |
| EXTENSION 2 GRANTED | 2015-07-11 | 50 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2015-07-14 | 51 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2015-12-21 | 52 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2015-12-21 | 53 EXT3 S: |
| EXTENSION 3 GRANTED | 2016-01-19 | 54 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2016-01-20 | 55 EXRA E:E-Mail |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2016-03-03 | 56 TCCA I:Incoming Correspondence |
| ABANDONMENT - NO USE STATEMENT FILED | 2016-08-01 | 57 ABN6 S: |
| ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | 2016-08-01 | 58 MAB6 O:Outgoing Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SOLBRI 85317171 not registered Dead/Abandoned |
Valeant International Bermuda 2011-05-10 |
 SOLBRI 78862981 not registered Dead/Abandoned |
Biovail Laboratories International SRL 2006-04-17 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 